BioDiem Ltd.'s BDM-I Presented at International Conference
Published: Sep 16, 2013
Melbourne, 16 September 2013: Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) has announced that antifungal study results relating to its novel antimicrobial BDM-I have been presented in a poster at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), run by the American Society of Microbiology, in Denver, Colorado.
The results were generated via the U.S. National Institute of Allergy and Infectious Diseases’ (NIAID’s) In Vitro Assessment for Antimicrobial Activity Service1*. Under NIAID’s preclinical services program, internationally recognised researchers, Professors Melanie Cushion3 and Thomas Patterson4,5 tested BDM-I’s activity against a range of fungi which can cause serious human infection. This was expanded testing following on from an earlier assessment. The poster titled “Antifungal and antipneumocystis activity of the investigational antimicrobial BDM-I” is attached to this announcement.
Nearly 70 different strains of opportunistic or hospital-acquired fungi have been assessed for sensitivity to BDM-I. These micro-organisms can all cause illnesses which are difficult to treat. Examples include life-threatening bloodstream infections and pneumonia.
In these bench-top studies, BioDiem’s BDM-I demonstrated activity against several of the Cryptococcus species as well as endemic fungi such as Blastomyces dermatitidis, Coccidioides immitis/posadasii and Histoplasma capsulatum. Marked activity was also demonstrated by BDM-I against Pneumocystis carinii and murina. It was noted by the researchers Professors Cushion and Patterson that “further studies are warranted to determine the potential of this broad-spectrum antifungal agent”.
Based on these encouraging results, BioDiem previously announced new studies to assess both optimal dose and overall effectiveness of BDM-I as a novel treatment in a mouse model of the fungal disease Pneumocystis. These studies are again supported by NIAID’s preclinical services program2**.
“The presentation of the data at this international conference and the progression of evaluation of BDM-I’s antifungal activity to studies in an animal model of pneumocystis infection is a significant step forward for BDM-I’s development program towards use in difficult-to-treat infections. This is where new treatments are urgently needed. BioDiem greatly appreciates NIAID support enabling this progress to occur” said BioDiem Chief Executive Julie Phillips.
Pneumocystis is a yeast-like fungus that many healthy people carry without symptoms. However in patients with a suppressed or compromised immune system such as cancer patients and particularly HIV patients, it is very problematic causing pneumonia which is a major cause of death in such patients who do not have preventative treatment.
According to the U.S. Centers for Disease Control and Prevention (CDC), Atlanta, the incidence of pneumocystis pneumonia (PCP) in the U.S. is estimated to be 9% among hospitalised HIV/AIDS patients and 1% among solid organ transplant recipients. In immunocompromised patients, the mortality rate ranges from 5% to 40% in those who receive treatment. The mortality rate approaches 100% without therapy.
In August 2012, BioDiem renewed its Non-Clinical Evaluation Agreement with NIAID, part of the U.S. National Institutes of Health (NIH), under which the research has progressed.
NIAID Contract Number * HHSN272201100018I ** HHSN2722010000029I
About BioDiem Ltd
BioDiem (ASX: BDM) is an ASX-listed biopharmaceutical company developing vaccines and antimicrobials targeting treatment and prevention of infectious diseases and related cancers. The lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine used for seasonal and pandemic influenza vaccines and is given intranasally. BDM-L, a therapeutic hepatitis vaccine project targeting hepatitis D and B is underway at the University of Canberra. BioDiem's antimicrobial, BDM-I, is in preclinical development for fungal and bacterial diseases, also schistosomiasis. The SAVINE (scrambled antigen) technology is in development for tuberculosis and also EBV-related disease including nasopharyngeal cancer. BioDiem's retinal product BDM-E, being developed for retinitis pigmentosa, is available for outlicence. BioDiem’s research is ongoing in partnerships with internationally recognised laboratories and commercial groups.
BDM-I is a synthetic compound targeting the treatment of serious human infections. BDM-I is in the preclinical stage with outlicensing as the intended outcome. BDM-I is active against a range of pathogenic micro-organisms including gram-positive and gram-negative bacteria, fungi and protozoa. Key patents have been granted in Europe, Japan and the US around BDM-I’s antimicrobial activity, including activity against Plasmodium falciparum, responsible for causing the most commonly severe form of malaria, and Trichomonas vaginalis, the protozoan responsible for causing trichomoniasis.
About National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
NIAID, part of NIH, conducts and supports research throughout the United States and worldwide to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing, and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
3About University of Cincinnati College of Medicine
The University of Cincinnati College of Medicine is one of 14 colleges of the University of Cincinnati—a top-ranked public research university with more than 42,000 students. In September 2012, UC was labeled “among the top tier of the best national universities” by U.S. News and World Report. The UC College of Medicine, established in 1819 as the Medical College of Ohio by pioneering physician Daniel Drake, became a part of the University of Cincinnati in 1896. The college is considered the oldest medical college in operation west of the Allegheny Mountains and is the second-oldest public college of medicine in the U.S. The College of Medicine has an exceptional list of alumni and current and past faculty who have made considerable contributions to medicine and to the medical sciences, including Albert Sabin, MD, who developed the live-virus oral polio vaccine.
4About The University of Texas Health Science Center at San Antonio
The University of Texas Health Science Center at San Antonio, one of the country’s leading health sciences universities, ranks in the top 3 percent of all institutions worldwide receiving National Institutes of Health funding. The university’s schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have produced more than 29,000 graduates. The $736 million operating budget supports eight campuses in San Antonio, Laredo, Harlingen and Edinburg. For more information on the many ways “We make lives better®,” visit www.uthscsa.edu.
5About South Texas Veterans Health Care System
South Texas Veterans Health Care System (STVHCS) serves one of the largest primary service areas in the nation providing health care services for about 80,000 Veterans in the San Antonio area.
For additional information, please visit www.biodiem.com
Julie Phillips, Chief Executive Officer
Phone +61 3 9613 4100
Phone +61 3 8866 1218 / +61 (0) 421 760 775
Help employers find you! Check out all the jobs and post your resume.